Coagulation factor V (FV) plays an important role in maintaining the hemostatic balance in both the formation of thrombin in the procoagulant pathway as well as in the protein C anticoagulant pathway. FV deficiency is a rare bleeding disorder with variable phenotypic expression. Little is known about the molecular basis underlying this disease. This study identified 5 novel mutations associated with FV deficiency in 3 patients with severe FV deficiency but different clinical expression and 2 unaffected carriers. Four mutations led to a premature termination codon either by a nonsense mutation (single-letter amino acid codes): A1102T, K310Term. (FV Amersfoort) and C2491T, Q773Term. (FV Casablanca) or a frameshift: an 8–base pair deletion between nucleotides 1130 and 1139 (FV Seoul1) and a 1–base pair deletion between nucleotides 4291 and 4294 (FV Utrecht). One mutation was a novel missense mutation: T1927C, C585R (FV Nijkerk), resulting in the absence of mutant protein despite normal transcription to RNA. Most likely, an arginine at this position disrupts the hydrophobic interior of the FV A2 domain. The sixth detected mutation was a previously reported missense mutation: A5279G, Y1702C (FV Seoul2). In all cases, the presence of the mutation was associated with type I FV deficiency. Identifying the molecular basis of mutations underlying this rare coagulation disorder will help to obtain more insight into the mechanisms involved in the variable clinical phenotype of patients with FV deficiency.

Human coagulation factor V (FV) is a single-chain glycoprotein that plays an important role in maintaining the hemostatic balance. It circulates in blood as an inactive procoagulant with a Mr of 330 kd and a structure consisting of 3 homologous A-type domains and 2 homologous C-type domains connected by a heavily glycosylated B domain in the order A1-A2-B-A3-C1-C2. Proteolytic cleavage by thrombin at R709, R1018, and R1545 (single-letter amino acid codes) results in removal of the B domain and converts the procofactor into the fully active cofactor FVa, which consists of a Mr 105-kd heavy chain (A1-A2) and a Mr 74- or 71-kd light chain (A3-C1-C2), associated via a single Ca++ion.1-3 The difference in molecular weight of the light chain reflects the presence of 2 isoforms of FVa (FVa1 and FVa2) due to alternative glycosylation of the C2 domain, which leads to different affinities for biologic membranes and subsequent overall procoagulant activity.4,5 In its active form, FVa forms an essential part of the prothrombinase complex that catalyzes the conversion of prothrombin to thrombin by factor Xa in the presence of calcium and a phospholipid membrane.1-3Activated protein C (APC) inactivates FVa through cleavage of the active cofactor at R306, R506, and R679 and requires FV as a cofactor in the APC-mediated inactivation of factor VIIIa (FVIIIa).6,7 Thus, FV plays an important role in the procoagulant pathway as well as in the protein C anticoagulant pathway. The structure of FV is similar to FVIII (both cofactors share approximately 40% homology in their heavy and light chains) and ceruloplasmin, the copper-binding protein in plasma.8,9 Recently, the crystal structure of the C2 domain of FV has been established10 and molecular models for the A and C domains of FV have been proposed.11 12 

The gene for coagulation FV has been mapped to chromosome 1q2313 and spans more than 80 kilobases (kb). It consists of 25 exons and the messenger RNA (mRNA) encodes a leader peptide of 28 amino acids and a mature protein of 2196 amino acids. Roughly, the heavy chain is encoded by exons 1 to 12 and the light chain by exons 14 to 25. The entire B domain is encoded by exon 13, which contains 2 tandem repeats of 17 amino acids and 31 tandem repeats of 9 amino acids that are absent in the B domain of FVIII.14 15 

Deficiency of FV, or parahemophilia, was first described in 1947 by Owren.16 It is a rare autosomal recessive bleeding disorder with an estimated frequency of one in one million. The phenotypic expression of FV deficiency is variable; heterozygotes are usually asymptomatic, whereas homozygous patients show mild, moderate, or severe bleeding symptoms. Identifying the molecular basis underlying this disease will help to obtain more insight into the mechanisms involved in this variable clinical expression. The recently published complete nucleotide sequence of the FV gene (GenBank accession number Z99572) has facilitated the molecular characterization underlying FV deficiency and reports have identified mutations in theFV gene that result in FV deficiency.17-30 To date, no compound heterozygous patients have been described. In the present study we used DNA sequence analysis to detect 5 novel mutations and one previously reported mutation in the FV gene of 3 patients, one of whom is the first characterized compound heterozygote, with severe FV deficiency and 2 asymptomatic carriers. All mutations resulted in type I FV deficiency.

Patients

Patient 1 is a 19-year-old woman from South Korea. She was adopted by a Dutch family at the age of 3 months. At the age of 19 months she developed bleeding of the soft tissue of the mouth. Severe FV deficiency, reflected by an FV activity less than 1% (Table1), was diagnosed. At the age of 4 years she experienced a large subdural hematoma, which completely resolved after frequent transfusions of fresh frozen plasma. Her bleeding pattern mostly showed soft tissue bleeds of the mouth, epistaxis, and hematomas for which she received fresh frozen plasma once every 3 months. In the last years her bleeding pattern changed to spontaneous muscle bleedings.

Patient 2 is a 5-year-old boy of Turkish ancestry. He was diagnosed at the age of 1 year, because of soft tissue bleed in his mouth that did not stop after conservative treatment. His laboratory tests demonstrated an FV activity less than 1%. His consanguineous parents both had lowered FV activity and antigen levels, suggesting a FV deficiency carrier status (Table 1). No clinical bleeding problems in the parents were apparent. The following years he frequently had bleeds of his mouth, hematomas, and epistaxis. Severe bleeding episodes were treated with fresh frozen plasma. Until now he has not had muscle or joint bleeds.

Patient 3 is a 15-year-old girl from Morocco. The diagnosis of severe FV deficiency, FV activity less than 1% (Table 1), was made following family screening. She does not have a bleeding tendency, but so far she has not had any operative procedures or injuries. Her parents are first-degree cousins. Her 23-year-old brother also has a severe FV deficiency. Other than prolonged bleeding after injuries, he has had no bleeding problems. He has been described before.31 

Patients 4 and 5 are both asymptomatic Dutch individuals who were discovered during routine laboratory testing. They presented with normal to slightly prolonged activated partial thromboplastin time (APTT), respectively, 31 and 34 seconds (reference values, 24-32 seconds), and slightly prolonged prothrombin time (PT), respectively, 13.6 and 13.8 seconds (reference values, 11.0-13.0 seconds). Liver failure and all other possible causes of aberrant APTT and PT results were excluded. FV activity and antigen levels were decreased (Table 1).

Informed consent was obtained from all patients and family members.

Control group

The control group consisted of 50 unrelated healthy laboratory employees of Caucasian origin. Their DNA was used to establish the allelic frequencies of exonic polymorphisms and the occurrence of the T1927C missense mutation by testing the appropriate base change either by restriction enzyme analysis or by DNA sequence analysis. Informed consent was obtained from all control individuals.

Blood collection for coagulation tests

Venous blood was collected into plastic tubes in 1/10 volume of 3.8% sodium citrate. Platelet-poor plasma was obtained by centrifugation at 1200g for 20 minutes at room temperature and aliquots were immediately stored at −80°C until testing.

FV coagulant activity and FV antigen

Activity of FV was measured on an STA coagulation analyzer (Roche, Mannheim, Germany) by performing a PT in a plasma sample diluted with FV-deficient plasma. FV antigen was determined by Professor Rogier M. Bertina by measuring FV light chain by an enzyme-linked immunosorbent assay (ELISA) as described.20 

Isolation of DNA and RNA

DNA was isolated from peripheral white blood cells using the Puregene DNA isolation kit (Gentra Systems, Minneapolis, MN) according to the manufacturer's instructions. Lymphocytes were isolated from whole blood using Ficoll-Pague (Pharmacia, Uppsala, Sweden) and total RNA was extracted as described.32 

Amplification of the FV gene

Nucleotides are numbered according to Jenny and colleagues.14 Nucleotides in the putative promoter region are numbered relative to the initiation codon. The primers used for polymerase chain reaction (PCR) amplification and DNA sequence analysis of the promoter and the individual exons are listed in Table2. Intronic primers were chosen at appropriate distance from the splice sites. The large exon 13 was divided into 5 fragments (a-e). The PCR reactions were carried out with 50 to 100 ng DNA in 100 μL volumes containing 10 mM Tris-HCL, pH 8.3, 50 mM KCL, 1.5 mM MgCl2, 0.01% (wt/vol) gelatin, 0.2 mM of each dNTP, 0.3 μM of each primer, and 2.5 U AmpliTaq DNA polymerase. All reagents were obtained from Perkin Elmer (Roche Molecular Systems, Branchburg, NJ). The samples were subjected to 30 or 35 cycles of amplification with denaturation at 94°C for 30 seconds (5 minutes at 95°C prior to the first cycle), annealing for 30 seconds at 50 to 64°C (Table 2) and extension at 72°C for 30 to 60 seconds followed by an elongated extension time of 10 minutes after the last cycle.

DNA sequence analysis

Automated DNA sequence analysis was performed with the ABI Prism dRhodamine Terminator Cycle Sequencing Ready Reaction Kit (PE Biosystems, Warrington, England), according to the manufacturer's instructions. Sequencing reactions were all carried out in forward and reverse direction, and samples were analyzed on an Applied Biosystems ABI 310 Genetic Analyzer (Applied Biosystems, Foster City, CA). The PCR products were purified prior to DNA sequence analysis with the QIAquick PCR purification kit (Qiagen, Valencia, CA) or excised from the agarose gel and purified using the Prep-A-Gene DNA Purification Kit (Biorad Laboratories, Hercules, CA) according to instructions.

Reverse transcription-PCR

Reverse transcription-PCR (RT-PCR) to detect the T1927C mutation was performed using the GeneAmp RNA PCR Kit from Perkin Elmer (Roche Molecular Systems, Branchburg, NJ) according to the instructions of the manufacturer. Briefly, 0.3 to 1.0 μg total RNA was reverse transcribed using random hexamers as primers. After addition of 30 pmol of primers HCFV-C11F 5′-ATGAGGTGAAACGTGATGACC-3′, exon 11 nts 1802 to 1822 and HCFV-C12R 5′-ACCGTCACAGATTCTCCACG-3′, exon 12 nts 2048 to 2029, the samples were subjected to 35 cycles of amplification with denaturation at 94°C for 30 seconds (5 minutes at 95°C prior to the first cycle), annealing at 58°C for 30 seconds, and extension at 72°C for 30 seconds, followed by an elongated extension time of 10 minutes after the last cycle. Total liver RNA was used as a positive control and controls without RNA as well as controls in which the reverse transcription step was omitted were included.

Restriction enzyme analysis

All mutations were confirmed by restriction enzyme analysis on a newly amplified PCR product (Table 3). The 8-bp deletion in exon 7 was confirmed by MboII digestion. The PCR product as amplified with primers HCFV-7F and HCFV-7R is 241 bp and contains one restriction site forMboII. Digestion of the wild-type allele results in fragments of 134 and 107 bp. The deletion abolishes this site, rendering a single fragment of 233 bp.

To confirm the T1927C mutation, exon 12 was amplified with primers HCFV-12F and HCFV-12R and subjected to BslI digestion. The 286-bp PCR product from the wild-type allele contains one restriction site for BslI, yielding fragments of 214 and 72 bp. The mutation creates a second restriction site resulting in additional fragments of 117 and 97 bp. The 247-bp PCR product containing exon 12, as obtained by RT-PCR with primers HCFV-C11F and HCFV-C12R, yields fragments of 228 and 19 bp for the wild-type allele and 131, 97, and 19 bp for the T1927C allele, following digestion with BslI.

The C2491T nonsense mutation in exon 13 was confirmed byHphI digestion of the 5′ end of exon 13 as amplified with primers HCFV-13aF and HCFV-13aR. The 605-bp PCR product normally contains one recognition site for HphI, producing fragments of 458 and 147 bp, which is abolished by this base change and thus results in an uncut PCR product from the mutant allele.

To detect the A5279G mutation, the PCR product (600 bp) amplified with primers HCFV-15F2 and HCFV-15R, containing exon 15, was subjected to digestion with Cac8I. The mutation adds an extra restriction site to the one normally present in this fragment; 338-, 55-, and 207-bp fragments are produced in contrast to the wild-type allele, 338 and 262 bp.

In general, 20 μL of the appropriate PCR product was incubated with 10 to 20 U of the respective enzymes. All enzymes were purchased from New England Biolabs (Beverly, MA).

Molecular modeling

A 3-dimensional diagram of the cysteine at residue 585 in FV was generated from an FV homology model12 using computer programs Molscript33 and Raster3D.34 

FV activity and antigen

Factor V activity and antigen results of the propositae and relevant family members are summarized in Table 1. In all subjects, excluding patient 3 from whom plasma was unavailable, the reduction of FV activity correlated with a similar reduction of FV antigen, indicating a type I FV deficiency.

Molecular analysis

During the course of the DNA sequence analysis of the completeFV gene of the patients, relevant relatives, and a control subject, a number of novel base changes as compared to the published sequence were identified. One was located in the promoter, 15 in the coding region, and 19 in the noncoding region. The intronic base changes were excluded from being the (primary) genetic defect underlying the FV deficiency, based on the fact that they were not located in or near consensus sequence motifs considered critical for RNA processing, neither did they create any such sequence.35 36 They were therefore considered to be polymorphisms. Likewise, the promoter base change at nt −426 was considered to be polymorphic given its high frequency in the control group. We report the allelic frequencies of all applicable exonic base changes, except for the 2 frameshift mutations and nonsense mutants, as determined in the control group. The results obtained from the molecular analysis are summarized in Table 3.

Patient 1

By DNA sequence analysis, this patient was found to be heterozygous for a novel deletion in exon 7, where 8 bp ((TG)AAGAGG(TG)) were deleted between nts 1130 and 1139 (Figure1), resulting in a frameshift and a premature stop codon at residue 351. This mutation was confirmed byMboII digestion. Because the patient had undetectable levels of FV activity and antigen (Table 1), we postulated her to be a probable compound heterozygote. Further DNA sequence analysis revealed, apart from 6 previously published polymorphisms (G1628A,37,38 (A2663G, A2684G, A2863G),14,15,39,40 C4279T41 and A5380G,42-44) one other base change in the heterozygous state: exon 15: A5279G, Y1702C. Because she was an orphan without any known relatives, it was not possible to determine which changes occurred in trans of the 8-bp deletion by linkage analysis. However, the A5279G mutation has recently been associated with FV deficiency25 and is therefore most likely the causative mutation on the other FV allele of this patient. This missense mutation was confirmed by Cac8I digestion. We named this compound heterozygous variant FV Seoul1,2.

Fig. 1.

Predicted truncated FV molecules as encoded by the FV frameshift and nonsense mutations detected in this study.

Schematic representation shows the 25 exons of the FV gene and the procoagulant protein that consists of a heavy chain (A1-A2), a connecting region or B domain, and a light chain (A3-C1-C2). The position of the mutation in the gene and in the DNA sequencing electropherogram as well as the predicted premature translation stop in the protein are indicated by arrows. The 3 cytosines resulting from the 1-bp deletion in patient 2 are underlined. Dashed lines in the protein indicate the part that is lacking, as compared to the wild-type protein. Patient 1: heterozygous 8-bp deletion between nts 1130 and 1139 in exon 7 leading to a premature stop at codon 351. Patient 2: homozygous 1-bp deletion between nts 4291 and 4294 in exon 13 leading to a premature stop at codon 1381. Patient 3: homozygous C→T nonsense mutation at nt 2491 in exon 13, changing the codon for glutamine at residue 773 into a stop codon. Patient 4: heterozygous A→T nonsense mutation at nt 1102 in exon 7, changing the codon for lysine at residue 310 into a stop codon. W: A or T

Fig. 1.

Predicted truncated FV molecules as encoded by the FV frameshift and nonsense mutations detected in this study.

Schematic representation shows the 25 exons of the FV gene and the procoagulant protein that consists of a heavy chain (A1-A2), a connecting region or B domain, and a light chain (A3-C1-C2). The position of the mutation in the gene and in the DNA sequencing electropherogram as well as the predicted premature translation stop in the protein are indicated by arrows. The 3 cytosines resulting from the 1-bp deletion in patient 2 are underlined. Dashed lines in the protein indicate the part that is lacking, as compared to the wild-type protein. Patient 1: heterozygous 8-bp deletion between nts 1130 and 1139 in exon 7 leading to a premature stop at codon 351. Patient 2: homozygous 1-bp deletion between nts 4291 and 4294 in exon 13 leading to a premature stop at codon 1381. Patient 3: homozygous C→T nonsense mutation at nt 2491 in exon 13, changing the codon for glutamine at residue 773 into a stop codon. Patient 4: heterozygous A→T nonsense mutation at nt 1102 in exon 7, changing the codon for lysine at residue 310 into a stop codon. W: A or T

Close modal

Patient 2

DNA sequence analysis revealed a novel homozygous deletion in exon 13 where one cytosine was deleted from a series of 4 cytosines present between nts 4291 and 4294 (Figure 1). This resulted in a frameshift leading to a premature translation stop at codon 1381. Both parents, who were first cousins, were heterozygous for the same deletion thereby excluding the possibility of hemizygosity in the propositus due to a large deletion. We designated this variant FV Utrecht.

Patient 3

The FV gene of this patient showed a novel homozygous nonsense mutation in exon 13 where a C→T substitution at nt 2491 predicted a stop codon at residue 773 instead of the wild-type glutamine (Figure 1). This mutation was confirmed by HphI digestion and we named this variant FV Casablanca.

Patient 4

This patient was found to have a single heterozygous A→T base change at nt 1102 in exon 7 (Figure 1), thereby changing the codon for lysine at residue 310 into a termination codon. All available family members were tested for this mutation and the nonsense mutation cosegregated with reduced FV activity and antigen levels (Table 1). This mutant was designated FV Amersfoort.

Apart from this nonsense mutation and a previously described heterozygous polymorphism (G409C),45 we identified a novel homozygous base substitution in exon 24: T6533C, M2120T. Because this substitution concerns a conserved residue in the C2 domain of FV, its occurrence was investigated in the control group (Table 3). T6533C appeared to be a rare polymorphism of which all of the children in this family are obligate carriers, whereas the spouse of the patient is a wild-type homozygote (data not shown). The 2 children in this family who lack the A1102T mutation had normal FV activity levels (Table 1), so any (additional) effect of this amino acid substitution to the more pronounced reduction in FV activity of the propositus compared to his 2 sons (34% versus 62% and 60%) was not likely to be due to the fact that he was homozygous for this rare polymorphism.

Patient 5

We identified 6 nucleotide substitutions linked to lowered activity and antigen levels in this family. Five were previously reported polymorphisms: (A2663G, A2684G, A2863G),14,15,39,40 C4300T,41 and A5380G,42-44 whereas one was a novel T→C substitution at nt 1927 in exon 12, coding for a C→R change at residue 585. We investigated the occurrence of T1927C in a normal population but found no control subjects carrying this allele (Table 3). We postulated the T1927C base change to cause FV deficiency (see “Discussion”) in this family (Table 1 and Figure 2) and named this variant FV Nijkerk. The mutant allele was transcribed to RNA, because the mutant RNA could be detected, by RT-PCR, in both the patient and his mother (Figure 2).

Fig. 2.

Detection of the T1927C missense mutation in the family pedigree and mutant RNA.

(Top) Family pedigree: individuals heterozygous for the T1927C (FV Nijkerk) missense mutation are indicated by a half-closed symbol. (Middle) Exon 12 was amplified from genomic DNA and subjected toBsl I digestion as described. The mutation creates an additional restriction site and the resulting fragments are indicated by arrows. Each lane represents the DNA from the individuals located directly above in the family pedigree in the top panel. (Bottom) Total RNA was reverse transcribed and amplified as described. SubsequentBsl I digestion revealed the presence of both the wild-type allele as well as the mutant allele in the RNA of patient 5 (III-1) and his mother (II-3). Asterisk indicates propositus; M, marker; C, liver tissue32 RNA control; PCR, uncut RT-PCR product (247 bp).

Fig. 2.

Detection of the T1927C missense mutation in the family pedigree and mutant RNA.

(Top) Family pedigree: individuals heterozygous for the T1927C (FV Nijkerk) missense mutation are indicated by a half-closed symbol. (Middle) Exon 12 was amplified from genomic DNA and subjected toBsl I digestion as described. The mutation creates an additional restriction site and the resulting fragments are indicated by arrows. Each lane represents the DNA from the individuals located directly above in the family pedigree in the top panel. (Bottom) Total RNA was reverse transcribed and amplified as described. SubsequentBsl I digestion revealed the presence of both the wild-type allele as well as the mutant allele in the RNA of patient 5 (III-1) and his mother (II-3). Asterisk indicates propositus; M, marker; C, liver tissue32 RNA control; PCR, uncut RT-PCR product (247 bp).

Close modal

Little is known about the molecular basis underlying FV deficiency due to its low frequency in the population combined with the complexity of the gene itself. In this study we investigated 3 patients with severe FV deficiency and 2 asymptomatic carriers from 5 different families. We identified 5 novel mutations and a recently published mutation associated with FV deficiency.

Patients 1, 2, and 3 all had severe FV deficiency and undetectable levels of FV. DNA sequence analysis of the FV gene revealed 2 novel frameshift mutations and a novel nonsense mutation associated with an FV null allele. Patients 2 and 3 were both homozygous for a mutation in exon 13, respectively, a 1-bp deletion between nts 4291 and 4294 and a C2491T nonsense mutation. Patient 1 was compound heterozygous for an 8-bp deletion in exon 7 and a missense mutation in exon 15: A5279G, Y1702C (FV Seoul2). The missense mutation was recently described in the heterozygous state as causative for FV deficiency.25 Our study provides further evidence for the postulation that the Y1702C change leads to FV deficiency, because neither FV activity nor FV antigen could be detected in our patient.

The 2 small deletions and the nonsense mutation in the FVgenes of patients 1, 2, and 3 would, if translated, result in truncated FV molecules. The 8-bp deletion between nts 1130 and 1139 in exon 7, −(TG)AAGAGG(TG) (FV Seoul1), in patient 1 results in a frameshift and would code for a peptide of only 350 amino acids long, lacking approximately half the heavy chain and the entire B domain and light chain (Figure 1). In patient 2, the deletion of a cytosine between nts 4291 and 4294 in exon 13 (FV Utrecht) results in a frameshift that would code for a premature translation stop at codon 1381. Consequently, this protein would lack approximately 20% of the B domain and the entire light chain (Figure 1). In patient 3, the C2491T nonsense mutation in exon 13 (FV Casablanca) predicts a premature stop instead of a glutamine at residue 773 and thereby encodes a protein that would consist of a FV heavy chain and only 63 amino acids of the B domain (Figure 1). Thus, this variant FV would lack approximately 90% of the B domain and the complete light chain.

In general, nonsense mRNAs resulting from frameshift and nonsense mutations are highly unstable, because they are subjected to nonsense-mediated mRNA decay (NMD),46-48 preventing the potentially deleterious effects of truncated proteins. Recent studies of FV RNA metabolism demonstrated the absence of RNA of the in trans non-FV Leiden allele in patients who are “pseudo homozygous” for FV Leiden due to either a nonsense mutation21 or a frameshift mutation19 in exon 13. Consequently, the frameshift and nonsense mutations in patients 1, 2, and 3 most likely are associated with an FV null allele. The patients presented with different phenotypes: patients 1 and 2 had moderate bleeding symptoms, whereas patient 3 was asymptomatic. Furthermore, patient 1 suffered from spontaneous muscle bleedings, whereas these were absent in patient 2. This variability in phenotypic expression has previously been observed in other FV-deficient patients. Moreover, as mentioned in earlier reports,49,50 there is a striking discrepancy between mice and man. FV null mice die either in utero or of fatal perinatal hemorrhage,49 whereas human patients with undetectable FV levels do survive. Table4 summarizes the clinical phenotype of all patients with severe FV deficiency described to date who have been characterized at the molecular level. There is a marked difference in age at diagnosis and clinical presentation. As shown by patients I, VI, XI, and XII in Table 4, similar residual amounts of FV are still associated with a different phenotypic expression. Also, individuals with the same mutation, between families (patients I and VI) and even within families (patients II and VII), show a different clinical bleeding pattern. Therefore, the clinical expression of FV deficiency most likely does not depend solely on the type of mutation but also on other, yet unknown, modulating factors.

Previously it has been proposed50,51 that in patients with severe FV deficiency a very low level of expression of FV may occur. Because trace amounts of FV are capable of generating a significant amount of thrombin,52 this would then result in a level of FV synthesis sufficient to mitigate the clinical phenotype. For instance, “ribosomal frameshifting” has previously been recognized as a mechanism able to partially rescue protein synthesis from genes harboring frameshift mutations,53-55and it has also been proposed to play a role in the phenotypic expression of FV deficiency caused by a frameshift mutation in exon 13.50 Mutations in exon 13 occur frequently in theFV gene (Table 5) and because the B domain is relatively unimportant for FV procoagulant function, “ribosomal frameshifting” may thereby reflect one of the modulating factors involved in the phenotypic differences observed in these patients. As shown in Table 4, however, mutations in exon 13 still can lead to a severe phenotypic expression of the disease.

In mammals, the basic mechanism by which nonsense transcripts are recognized and subjected to NMD is still poorly understood.48 Therefore, it cannot be excluded that any residual amount of stable nonsense FV mRNA could actually produce small amounts of (truncated) protein. These molecules could escape detection by the methods used, but still be of interest for their remaining function or potentially harmful effects in the procoagulant and anticoagulant pathways. In humans, the role of NMD as a modifier of the phenotypic consequences of nonsense mutations is becoming increasingly evident, for example, in β-thalassemia.56-58 Clearly, multiple factors are involved in modulating the phenotypic expression of FV deficiency. Therefore, studies using genotypic and phenotypic data are warranted to obtain insight in the mechanisms leading to the observed differences in phenotypic expression of severe FV deficiency.

Patients 4 and 5 were both asymptomatic and carriers of a novel FV null allele. However, because the presence and function of these FV variants could be studied only in individuals heterozygous for the mutation, we cannot exclude the presence of small amounts of mutant protein that would go by undetected because of the wild-type background. In patient 4, a novel nonsense mutation was identified: A1102T, K310Term (FV Amersfoort) that would code for a truncated protein lacking the A2 domain of the heavy chain, the complete B domain and the entire light chain (Figure 1). This mutation was found to cosegregate within the affected family with decreased FV activity and antigen levels. In patient 5, a novel base change was detected: T1927C, C585R (FV Nijkerk) that most likely represents the mutation associated with the decrease in FV activity and antigen levels. This missense mutation cosegregated with FV deficiency in the affected family and was not detected among 100 normal alleles. Although mutant RNA was detected, indicating transcription from the FV Nijkerk allele, FV antigen and activity levels were consistent with heterozygous type I FV deficiency. Apparently, substitution of C585 by arginine results in rapid degradation of FV, either before or immediately after secretion into the circulation. C585 is conserved among human, bovine, and murine FV, but not in FVIII and ceruloplasmin. Analysis of disulfide bridges and free cysteines in bovine FVa have not yielded conclusive data on the state of C589 (C585 in human FV).59 However, homology modeling of FV A domains based on the crystal structure of ceruloplasmin indicates that C585 is not involved in disulfide-bond formation.12 In the FV homology model C585 is completely buried inside the hydrophobic interior of the A2 domain. Substitution of a small and hydrophobic cysteine by a large and hydrophilic arginine would disrupt the tight packing interactions typical of protein interiors. As a consequence, the protein might be unstable and prone to intracellular proteolysis. If stable FV Nijkerk would be synthesized, functionality is doubtful because a potential thrombin cleavage site is created by the introduction of an arginine at residue 585, adjacent to S586. Cleavage by thrombin at this site would result in excision of a fragment from amino acids 585 to the next thrombin cleavage site at R709. This would disrupt the C-terminal end of the A2 domain, resulting in a loss of function or unstable protein.

Noteworthy with respect to the sister of the propositus in the family carrying the FV Nijkerk variant is the fact that her FV levels were consistently lower than in the other carriers of the T1927C mutation (Table 1). This may be explained by the fact that she inherited a FV HR2 allele from her father (data not shown). This variant FV, characterized by the H1299R substitution in the FV B domain, has been associated with reduced FV levels.60-62Phenotypically, she is therefore “pseudo homozygous” for FV HR2, a rare FV genotype that has been reported previously once by Castoldi and coworkers.25 They reported a family in which one member carried a FV missense mutation (Y1702C), associated with absence of the mutant protein in plasma, on the allele in trans of the FV HR2 allele. This family member also had lower FV levels as compared to carriers of only the missense mutation in the family.25 

This study brings the total number of mutations associated with FV deficiency described to date to 17. An overview is presented in Table 5where the mutations are listed according to their proposed mode of action. The majority of these mutations have been found in unique families; only the C1690T,22,23 C3571T,28A5279G (this study and reference 25) and G6395A29 have been found in more than one (unrelated) family. FV Seoul1,2 in this study is the first compound heterozygous patient described to date who is fully characterized at the molecular level and in whom 2 rare FV deficiency–associated mutations are combined that completely abolish FV synthesis. Identifying the molecular basis underlying this rare coagulation disorder will help to obtain more insight into the mechanisms involved in the variable clinical phenotype of FV-deficient patients.

The authors wish to sincerely thank Richard Dirven and Rogier Bertina (Department of Hematology, Hemostasis and Thrombosis Research Center, University Medical Center, Leiden, The Netherlands) for providing the FV light chain data and Bruno Villoutreix (Department of Bioinformatics-Blood Coagulation, University of Paris, France) for kindly providing the PDB file containing the model structure of the 3 FV A domains.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
Jenny
RJ
Tracy
PB
Mann
KG
The physiology and biochemistry of factor V.
Haemostasis and Thrombosis.
3rd ed.
Bloom
AL
Forbes
CD
Thomas
DP
Tuddenham
EGD
1994
465
476
Churchill Livingstone
Edinburgh
2
Tuddenham
EGD
Cooper
DN
Factor V: the Molecular Genetics of Haemostasis and Its Inherited Disorders. Oxford Monographs on Medical Genetics. Oxford
1994
182
193
Oxford University Press
United Kingdom
3
Rosing
J
Tans
G
Coagulation factor V: an old star shines again.
Thromb Haemost.
78
1997
427
433
4
Hoekema
L
Nicolaes
GA
Hemker
HC
Tans
G
Rosing
J
Human factor Va1 and factor Va2: properties in the procoagulant and anticoagulant pathways.
Biochemistry.
36
1997
3331
3335
5
Nicolaes
GA
Villoutreix
BO
Dahlbäck
B
Partial glycosylation of Asn2181 in human factor V as a cause of molecular and functional heterogeneity: modulation of glycosylation efficiency by mutagenesis of the consensus sequence for N-linked glycosylation.
Biochemistry.
38
1999
13584
13591
6
Kalafatis
M
Rand
MD
Mann
KG
The mechanism of inactivation of human factor V and human factor Va by activated protein C.
J Biol Chem.
269
1994
31869
31880
7
Váradi
K
Rosing
J
Tans
G
Pabinger
I
Keil
B
Schwarz
HP
Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: influence of the factor V R506Q mutation.
Thromb Haemost.
76
1996
208
214
8
Church
WR
Jernigan
RL
Toole
J
et al
Coagulation factors V and VIII and ceruloplasmin constitute a family of structurally related proteins.
Proc Natl Acad Sci U S A.
81
1984
6934
6937
9
Kane
WH
Davie
EW
Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders.
Blood.
71
1988
539
555
10
Macedo-Ribeiro
S
Bode
W
Huber
R
et al
Crystal structures of the membrane-binding C2 domain of human coagulation factor V.
Nature.
402
1999
434
439
11
Villoutreix
BO
Bucher
P
Hofmann
K
Baumgartner
S
Dahlbäck
B
Molecular models for the two discoidin domains of human blood coagulation factor V.
J Mol Model.
4
1998
268
275
12
Villoutreix
BO
Dahlbäck
B
Structural investigation of the A domains of human blood coagulation factor V by molecular modeling.
Protein Sci.
7
1998
1317
1325
13
Koeleman
BP
Reitsma
PH
Bakker
E
Bertina
RM
Location on the human genetic linkage map of 26 genes involved in blood coagulation.
Thromb Haemost.
77
1997
873
878
14
Jenny
RJ
Pittman
DD
Toole
JJ
et al
Complete cDNA and derived amino acid sequence of human factor V.
Proc Natl Acad Sci U S A.
84
1987
4846
4850
15
Cripe
LD
Moore
KD
Kane
WH
Structure of the gene for human coagulation factor V.
Biochemistry.
31
1992
3777
3785
16
Owren PA. Parahaemophilia: haemorrhagic diathesis due to absence of a previously unknown clotting factor. Lancet. 1947:446-448.
17
Murray
JM
Rand
MD
Egan
JO
Murphy
S
Kim
HC
Mann
KG
Factor VNew Brunswick: Ala221-to-Val substitution results in reduced cofactor activity.
Blood.
86
1995
1820
1827
18
Guasch
JF
Lensen
RP
Bertina
RM
Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is “pseudo homozygous” for activated protein C resistance.
Thromb Haemost.
77
1997
252
257
19
Castoldi
E
Kalafatis
M
Lunghi
B
et al
Molecular bases of pseudo-homozygous APC resistance: the compound heterozygosity for FV R506Q and a FV null mutation results in the exclusive presence of FV Leiden molecules in plasma.
Thromb Haemost.
80
1998
403
406
20
Guasch
JF
Cannegieter
S
Reitsma
PH
van 't Veer-Korthof
ET
Bertina
RM
Severe coagulation factor V deficiency caused by a 4 bp deletion in the factor V gene.
Br J Haematol.
101
1998
32
39
21
Lunghi
B
Castoldi
E
Mingozzi
F
Bernardi
F
Castaman
G
A novel factor V null mutation detected in a thrombophilic patient with pseudo-homozygous APC resistance and in an asymptomatic unrelated subject [letter].
Blood.
92
1998
1463
1464
22
Kitzis A, Salmeron S, Chomel JC, Boinot C, Patri S. Hum Genet. Gene symbol: FV; disease: factor V deficiency. 1999;104:290.
23
Mirochnik
O
Halim-Kertanegara
N
Henniker
AJ
et al
A novel factor V null mutation at Arg 506 causes a false positive Factor V Leiden result [letter].
Thromb Haemost.
82
1999
1198
1199
24
Zehnder
JL
Hiraki
DD
Jones
CD
Gross
N
Grumet
FC
Familial coagulation factor V deficiency caused by a novel 4 base pair insertion in the factor V gene: factor V Stanford.
Thromb Haemost.
82
1999
1097
1099
25
Castoldi
E
Simioni
P
Kalafatis
M
et al
Combinations of 4 mutations (FV R506Q, FV H1299R, FV Y1702C, PT 20210G/A) affecting the prothrombinase complex in a thrombophilic family.
Blood.
96
2000
1443
1448
26
Howard
J
Hughes
RG
Basu
S
et al
A novel mutation in the factor V gene causing a severe coagulation defect in two sisters [abstract].
Blood.
96
2000
642a
27
Montefusco
MC
Asselta
R
van Wijk
R
Duga
S
Tenchini
ML
Concerns about the mutations identified in a case of familial coagulation factor V deficiency: factor V Stanford [letter].
Thromb Haemost.
84
2000
1131
1132
28
Montefusco
MC
Duga
S
Asselta
R
et al
Severe factor V deficiency caused by two novel mutations in exon 13 of factor V gene [abstract].
Haematologica.
85(suppl to n. 5)
2000
95
29
Schrijver
I
Houissa-Kastally
R
Jones
CD
Zehnder
JL
Identification of a novel factor V C2-domain mutation (R2074H) in two separate families with factor V deficiency and bleeding [abstract].
Blood.
96
2000
533a
30
Montefusco
MC
Duga
S
Asselta
R
et al
A novel 2 bp deletion in the factor V gene associated with severe factor V deficiency.
Br J Haematol.
111
2000
1240
1246
31
Tanis
BC
van der Meer
FJ
Bloem
RM
Vlasveld
LT
Successful excision of a pseudotumour in a congenitally factor V deficient patient.
Br J Haematol.
100
1998
380
382
32
Lind
B
van Solinge
WW
Schwartz
M
Thorsen
S
Splice site mutation in the human protein C gene associated with venous thrombosis: demonstration of exon skipping by ectopic transcript analysis.
Blood.
82
1993
2423
2432
33
Kraulis
PJ
MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures.
J Appl Cryst.
24
1991
946
950
34
Merritt
EA
Bacon
DJ
Raster3D: photorealistic molecular graphics.
Methods Enzymol.
277
1997
505
524
35
Krawczak
M
Reiss
J
Cooper
DN
The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences.
Hum Genet.
90
1992
41
54
36
Cooper
DN
Krawczak
M
Antonarakis
SE
The nature and mechanisms of human gene mutation.
The metabolic and molecular basis of inherited disease.
7th ed.
Scriver
C
Beaudet
AL
Sly
WS
Valle
D
1995
259
291
McGraw Hill
New York, NY
37
Gandrille
S
Greengard
JS
Alhenc-Gelas
M
et al
Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. The French Network on the behalf of INSERM.
Blood.
86
1995
219
224
38
Helley
D
Besmond
C
Ducrocq
R
et al
Polymorphism in exon 10 of the human coagulation factor V gene in a population at risk for sickle cell disease.
Hum Genet.
100
1997
245
248
39
Kane
WH
Ichinose
A
Hagen
FS
Davie
EW
Cloning of cDNAs coding for the heavy chain region and connecting region of human factor V, a blood coagulation factor with four types of internal repeats.
Biochemistry.
26
1987
6508
6514
40
Shen
NL
Fan
ST
Pyati
J
Graff
R
LaPolla
RJ
Edgington
TS
The serine protease cofactor factor V is synthesized by lymphocytes.
J Immunol.
150
1993
2992
3001
41
Ohnishi
Y
Tanaka
T
Yamada
R
et al
Identification of 187 single nucleotide polymorphisms (SNPs) among 41 candidate genes for ischemic heart disease in the Japanese population.
Hum Genet.
106
2000
288
292
42
Kane
WH
Davie
EW
Cloning of a cDNA coding for human factor V, a blood coagulation factor homologous to factor VIII and ceruloplasmin.
Proc Natl Acad Sci U S A.
83
1986
6800
6804
43
Bayston
TA
Ireland
H
Olds
RJ
Thein
SL
Lane
DA
A polymorphism in the human coagulation factor V gene.
Hum Mol Genet.
3
1994
2085
44
Greengard
JS
Sun
X
Xu
X
Fernandez
JA
Griffin
JH
Evatt
B
Activated protein C resistance caused by Arg506Gln mutation in factor Va [letter].
Lancet.
343
1994
1361
1362
45
Cargill
M
Altshuler
D
Ireland
J
et al
Characterization of single-nucleotide polymorphisms in coding regions of human genes.
Nat Genet.
22
1999
231
238
46
Culbertson
MR
RNA surveillance: unforeseen consequences for gene expression, inherited genetic disorders and cancer.
Trends Genet.
15
1999
74
80
47
Czaplinski
K
Ruiz-Echevarrı́a
MJ
González
CI
Peltz
SW
Should we kill the messenger? The role of the surveillance complex in translation termination and mRNA turnover.
Bioessays.
21
1999
685
696
48
Frischmeyer
PA
Dietz
HC
Nonsense-mediated mRNA decay in health and disease.
Hum Mol Genet.
8
1999
1893
1900
49
Cui
J
O'Shea
KS
Purkayastha
A
Saunders
TL
Ginsburg
D
Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V.
Nature.
384
1996
66
68
50
Yang
TL
Cui
J
Taylor
JM
Yang
A
Gruber
SB
Ginsburg
D
Rescue of fatal neonatal hemorrhage in factor V deficient mice by low level transgene expression.
Thromb Haemost.
83
2000
70
77
51
Lak
M
Sharifian
R
Peyvandi
F
Mannucci
PM
Symptoms of inherited factor V deficiency in 35 Iranian patients.
Br J Haematol.
103
1998
1067
1069
52
Mann
KG
How much factor V is enough?
Thromb Haemost.
83
2000
3
4
53
Hu
PY
Waheed
A
Sly
WS
Partial rescue of human carbonic anhydrase II frameshift mutation by ribosomal frameshift.
Proc Natl Acad Sci U S A.
92
1995
2136
2140
54
Linton
MF
Raabe
M
Pierotti
V
Young
SG
Reading-frame restoration by transcriptional slippage at long stretches of adenine residues in mammalian cells.
J Biol Chem.
272
1997
14127
14132
55
Young
M
Inaba
H
Hoyer
LW
Higuchi
M
Kazazian
HH
Jr
Antonarakis
SE
Partial correction of a severe molecular defect in hemophilia A, because of errors during expression of the factor VIII gene.
Am J Hum Genet.
60
1997
565
573
56
Hall
GW
Thein
S
Nonsense codon mutations in the terminal exon of the β-globin gene are not associated with a reduction in β-mRNA accumulation: a mechanism for the phenotype of dominant β-thalassemia.
Blood.
83
1994
2031
2037
57
Thermann
R
Neu-Yilik
G
Deters
A
et al
Binary specification of nonsense codons by splicing and cytoplasmic translation.
EMBO J.
17
1998
3484
3494
58
Romão
L
Inácio
A
Santos
S
et al
Nonsense mutations in the human beta-globin gene lead to unexpected levels of cytoplasmic mRNA accumulation.
Blood.
96
2000
2895
2901
59
Xue
J
Kalafatis
M
Silveira
JR
Kung
C
Mann
KG
Determination of the disulfide bridges in factor Va heavy chain.
Biochemistry.
33
1994
13109
13116
60
Lunghi
B
Iacoviello
L
Gemmati
D
et al
Detection of new polymorphic markers in the factor V gene: association with factor V levels in plasma.
Thromb Haemost.
75
1996
45
48
61
Alhenc-Gelas
M
Nicaud
V
Gandrille
S
et al
The factor V gene A4070G mutation and the risk of venous thrombosis.
Thromb Haemost.
81
1999
193
197
62
de Visser
MC
Guasch
JF
Kamphuisen
PW
Vos
HL
Rosendaal
FR
Bertina
RM
The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis.
Thromb Haemost.
83
2000
577
582
63
Koeleman
BP
Reitsma
PH
Allaart
CF
Bertina
RM
Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families.
Blood.
84
1994
10311035
64
Kostka
H
Siegert
G
Gehrisch
S
Kuhlisch
E
Runge
E
Jaross
W
New missense mutation in exon 13 (N789T) of the coagulation factor V gene.
Hum Mutat.
14
1999
357
65
Castoldi
E
Rosing
J
Girelli
D
et al
Mutations in the R2 FV gene affect the ratio between the two FV isoforms in plasma.
Thromb Haemost.
83
2000
362
365

Author notes

Wouter W. van Solinge, Department of Clinical Chemistry, University Medical Center, Postbus 85500, 3508 GA, Utrecht, The Netherlands; e-mail: wsolinge@lab.azu.nl.

Sign in via your Institution